MRVI
MARAVAI LIFESCIENCES HOLDINGS, INC.
Overview
Maravai LifeSciences provides critical products and services for biopharmaceutical development, including complex nucleic acids, custom enzymes, and antibody-based impurity detection solutions.
MARAVAI LIFESCIENCES HOLDINGS, INC is a Healthcare company operating in Biotechnology with a $1.94B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 9, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1014 Q&A exchanges
- Q4 FY2025Earnings2026-02-2617 Q&A exchanges
- Q3 FY2025Earnings2025-11-0614 Q&A exchanges
- Q2 FY2025Earnings2025-08-1120 Q&A exchanges
- Q1 FY2025Earnings2025-05-1316 Q&A exchanges
- Q4 FY2024Earnings2025-03-2017 Q&A exchanges
- Q3 FY2024Earnings2024-11-099 Q&A exchanges
- Q2 FY2024Earnings2024-08-0818 Q&A exchanges
- Q1 FY2024Earnings2024-05-0821 Q&A exchanges
- Q4 FY2023Earnings2024-02-2319 Q&A exchanges
- Q3 FY2023Earnings2023-11-088 Q&A exchanges
- Q2 FY2023Earnings2023-08-0820 Q&A exchanges
- Q1 FY2023Earnings2023-05-0819 Q&A exchanges
- Q4 FY2022Earnings2023-02-2211 Q&A exchanges
- Q3 FY2022Earnings2022-11-0223 Q&A exchanges
- Q2 FY2022Earnings2022-08-0727 Q&A exchanges
- Q1 FY2022Earnings2022-05-0820 Q&A exchanges
- Q4 FY2021Earnings2022-02-2318 Q&A exchanges
- Q3 FY2021Earnings2021-11-1017 Q&A exchanges
- Q2 FY2021Earnings2021-08-1020 Q&A exchanges
- Q1 FY2021Earnings2021-05-1026 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-09EPS— vs $-0.05—Rev— vs ——EODHD
- Q1 FY20262026-05-10EPS$0.01 vs $-0.06+100.0%Rev$65.8M vs ——EODHD
- Q4 FY20252026-02-24EPS$-0.04 vs $-0.07+43.0%Rev$49.9M vs ——EODHD
- Q3 FY20252025-11-05EPS$-0.08 vs $-0.080.0%Rev$41.6M vs ——EODHD
- Q2 FY20252025-08-10EPS$-0.08 vs $-0.07-14.3%Rev$47.4M vs ——EODHD
- Q1 FY20252025-05-22EPS$-0.02 vs $-0.020.0%Rev$46.9M vs ——EODHD
- Q4 FY20242025-02-19EPS$-0.06 vs $-0.04-49.6%Rev$56.4M vs ——EODHD
- Q3 FY20242024-11-06EPS$-0.02 vs $-0.01-100.0%Rev$65.2M vs ——EODHD
- Q2 FY20242024-08-06EPS$-0.06 vs $-0.00-100.0%Rev$73.4M vs ——EODHD
- Q1 FY20242024-05-07EPS$-0.02 vs $-0.03+33.3%Rev$64.2M vs ——EODHD
- Q4 FY20232024-02-21EPS$0.01 vs $-0.01+100.0%Rev$74.1M vs ——EODHD
- Q3 FY20232023-11-06EPS$-0.01 vs $0.01-100.0%Rev$66.9M vs ——EODHD
- Q2 FY20232023-08-06EPS$-0.05 vs $0.01-100.0%Rev$68.9M vs ——EODHD
- Q1 FY20232023-05-07EPS$0.03 vs $0.04-25.0%Rev$79.0M vs ——EODHD
- Q4 FY20222023-02-21EPS$0.35 vs $0.34+2.9%Rev$204.7M vs ——EODHD
- Q3 FY20222022-11-01EPS$0.37 vs $0.33+12.1%Rev$191.3M vs ——EODHD
- Q2 FY20222022-08-03EPS$0.54 vs $0.45+20.0%Rev$242.7M vs ——EODHD
- Q1 FY20222022-05-04EPS$0.54 vs $0.44+22.7%Rev$244.3M vs ——EODHD
- Q4 FY20212022-02-22EPS$0.45 vs $0.38+18.4%Rev$228.4M vs ——EODHD
- Q3 FY20212021-11-09EPS$0.44 vs $0.35+25.7%Rev$204.8M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-09 | — | $-0.05 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $0.01 | $-0.06 | +100.0% | $65.8M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-0.04 | $-0.07 | +43.0% | $49.9M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.08 | $-0.08 | 0.0% | $41.6M | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.08 | $-0.07 | -14.3% | $47.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-22 | $-0.02 | $-0.02 | 0.0% | $46.9M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $-0.06 | $-0.04 | -49.6% | $56.4M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.02 | $-0.01 | -100.0% | $65.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.06 | $-0.00 | -100.0% | $73.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.02 | $-0.03 | +33.3% | $64.2M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $0.01 | $-0.01 | +100.0% | $74.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.01 | $0.01 | -100.0% | $66.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-0.05 | $0.01 | -100.0% | $68.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $0.03 | $0.04 | -25.0% | $79.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $0.35 | $0.34 | +2.9% | $204.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $0.37 | $0.33 | +12.1% | $191.3M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.54 | $0.45 | +20.0% | $242.7M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $0.54 | $0.44 | +22.7% | $244.3M | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $0.45 | $0.38 | +18.4% | $228.4M | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $0.44 | $0.35 | +25.7% | $204.8M | — | — | EODHD |
Source: EODHD. MRVI reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks MRVI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.99 | $2.18 | -8.5% | -1.7% | -1.9% |
| Q4 FY2026 | $2.06 | $2.15 | -4.4% | +3.3% | +0.8% |
| Q3 FY2026 | $1.87 | $2.09 | -10.6% | +5.5% | +3.3% |
| Q2 FY2026 | $1.88 | $2.22 | -15.1% | -0.4% | -1.7% |
| Q1 FY2025 | $2.21 | $2.24 | -1.4% | -4.8% | -7.7% |
| Q4 FY2025 | $2.20 | $2.24 | -1.8% | +0.3% | -0.8% |
| Q3 FY2025 | $2.05 | $2.17 | -5.3% | +4.3% | +4.4% |
| Q2 FY2025 | $1.76 | $2.09 | -15.9% | -3.8% | -2.7% |
| Q1 FY2024 | $2.08 | $2.35 | -11.3% | -4.8% | -7.5% |
| Q4 FY2024 | $2.13 | $2.30 | -7.6% | +4.5% | +7.0% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Maintained2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Bernd BrustCEO1 yr4 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Rajesh AsarpotaCFO1 yr4 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Kevin HerdeCFO1 yr 4 mo17 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Peter Michael LeddySee Remarks1 yr 3 mono recorded callsCurrentSample
OTHER since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- Christine DolanSee Remarks1 yr 4 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
- Kurt OreshackGeneral Counsel1 yr 4 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MRVI.
$ curl https://api.spokenalpha.com/v1/companies/MRVIFAQ
Frequently asked about MRVI
Where can I find MARAVAI LIFESCIENCES HOLDINGS, INC.'s (MRVI) earnings call transcripts?
Spoken Alpha indexes MRVI's earnings call transcripts at https://spokenalpha.com/companies/MRVI. Each call links to attributed speakers and parsed analyst Q&A. MARAVAI LIFESCIENCES HOLDINGS, INC.'s own investor relations page is at https://investors.maravai.com/.
When was MARAVAI LIFESCIENCES HOLDINGS, INC.'s most recent earnings call?
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) held its most recent earnings call on 2026-05-10, covering fiscal Q1 2026.
What sector is MRVI in?
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) operates in the Healthcare sector (Biotechnology industry).